Skip to main content
Premium Trial:

Request an Annual Quote

PredictImmune, Addenbrooke's Hospital Sign Agreement to Provide IBD Diagnostic in UK, Ireland

NEW YORK (GenomeWeb) – PredictImmune announced today that it has entered a commercial agreement with Addenbrooke's Hospital — part of Cambridge University Hospitals National Health Service Foundation Trust — to provide the company's PredictSure IBD prognostic assay to clinicians and gastroenterologists in the UK and Ireland.

As part of the agreement, the hospital's East Midlands and East of England Genomic Laboratory hub will manage and facilitate fulfillment of PredictSure IBD orders, in addition to receiving and processing all samples.

PredictImmune's CE-IVD PredictSure platform integrates a blood-based biomarker assay and a proprietary algorithm to identify biomarkers linked to irritable bowel disease (IBD), including Crohn's disease and ulcerative colitis.

PredictImmune said that the agreement will help both clinicians and patients understand the likely course of disease and makes available more treatment choices from initial diagnosis.

"Partnering with Addenbrooke's to make PredictSure available across the UK and Ireland feels very appropriate, given the long-term nature of our collaboration to date," PredictImmune CEO Paul Kinnon said in a statement. "We are excited to see PredictSure IBD become available to UK and Irish patients, particularly because we understand the life-changing benefits that early and accurate prediction of the likely course of their IBD diseases can have on their quality of life."

Financial details of the agreement were not disclosed.

PredictImmune previously announced in March the entry of PredictSure IBD into NICE's Diagnostic Assessment Programme, which evaluates new diagnostic technologies for the UK's NHS.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.